AdisInsight conducted an analysis of potential drug candidates that are expected to achieve milestones, setting themselves apart as blockbusters or breakthrough treatments. A study on the potential of future drugs in neuroscience, endocrinology, oncology, rare diseases, chronic blood disorders, and their anticipated impact on market trends will be released later this year.
The session will examine drugs that are vigorously impacting market revenue due to the following:
- Reducing patient burden
- Being the first stem cell therapy using CRISPR/Cas9 technology
- Improving quality of life
- Being the first combination of chemotherapy and hormonal cancer therapy
AdisInsight experts will also highlight the regulatory milestones of these drugs and explore how clinical trial data influenced their approval process. Join this webinar to learn about AdisInsight's report on potential breakthrough drugs.
Speaker
Samreen Shaikh
Lead Pharma Solutions
Springer Nature
Samreen Shaikh is the Lead Pharma Solutions at Springer Nature, Pune, with over 15 years of experience in the field, including 6 years in Pharma Solutions at Springer Nature. She joined Springer Nature in 2018 and has been instrumental in handling new initiatives and is a subject matter expert in the AdisInsight team. Additionally, Ms. Shaikh has an impressive academic background, with 9 years of experience as an Assistant Professor at Pune University, India. She holds an M.S. (Pharm) degree specializing in Medicinal Chemistry from National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India.
Register for free webinar
June 20, 2024 | 9 am CET | 4 pm JST